Grace Breeding’s NFT Bio-Fertilizer Receives its First European Product Registration Approval in Austria for Use in Wheat and Corn
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH)…
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH)…
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process…
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process…
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues…
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues…
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation…
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation…
– V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc….